Chronic Plaque Psoriasis - Pipeline Review, Q4 2010
Summary
Global Markets Direct’s, “Chronic Plaque Psoriasis Pipeline Review, Q4 2010”, provides an overview of the Chronic Plaque Psoriasis therapeutic pipeline. This report provides information on the therapeutic development for Chronic Plaque Psoriasis , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis . “Chronic Plaque Psoriasis -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Markets Direct’s, “Chronic Plaque Psoriasis Pipeline Review, Q4 2010”, provides an overview of the Chronic Plaque Psoriasis therapeutic pipeline. This report provides information on the therapeutic development for Chronic Plaque Psoriasis , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis . “Chronic Plaque Psoriasis -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- A snapshot of the global therapeutic scenario for Chronic Plaque Psoriasis .
- A review of the Chronic Plaque Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Plaque Psoriasis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- A snapshot of the global therapeutic scenario for Chronic Plaque Psoriasis .
- A review of the Chronic Plaque Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Plaque Psoriasis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Introduction
Global Markets Direct Report Coverage
Chronic Plaque Psoriasis Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Plaque Psoriasis
Chronic Plaque Psoriasis Therapeutics under Development by Companies
Chronic Plaque Psoriasis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Chronic Plaque Psoriasis Therapeutics Development
Johnson & Johnson
Boehringer Ingelheim GmbH
Abbott Laboratories
Amgen Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Biotest AG
Merck & Co., Inc.
Nycomed International Management GmbH
Novartis AG
Astellas Pharma Inc.
Galderma S.A.
GTC Biotherapeutics, Inc.
UCB Group
Incyte Corporation
Merck KGaA
Paladin Labs Inc.
CombinatoRx, Incorporated
R-Tech Ueno, Ltd.
Eisai Inc.
REVOTAR Biopharmaceuticals AG
Therapeutics Incorporated
Vascular Biogenics Ltd.
ISDIN
AB Science
Maruho Co.,Ltd.
Universities/Institutes Involved in Chronic Plaque Psoriasis Therapeutics Development
Chronic Plaque Psoriasis Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
ABT-874 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Calcipotriene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Halobetasol Propionate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Humira + Daivobet - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methotrexate + Enbrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NYC 0462 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Onercept_ - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Voclera - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Alga Dunaliella bardawil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Humira - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pioglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Chronic Plaque Psoriasis - Featured News
Sep 14, 2010: Biotie's Phase I Trial With BTT-1023 Demonstrates Safety Profile
Oct 19, 2009: New Simponi Data Show Inhibition of Joint Damage in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
Oct 19, 2009: New Simponi Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
Oct 06, 2009: Simponi (golimumab) Receives European Approval As Once-Monthly Subcutaneous Anti-Tnf For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis With Novel Smartject Autoinjector.
Jun 25, 2009: SIMPONI(Golimumab) Receives Positive Opinion from Chmp for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Apr 24, 2009: Simponi (Golimumab) Receives FDA Approval As First Once-Monthly Anti-TNF For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis
Apr 13, 2009: Health Canada Approves Simponi™ (Golimumab) For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis
Sep 05, 2008: BioCryst Reports Results From BCX-4208 Phase IIa Trial In Subjects With Psoriasis
Apr 14, 2008: Medarex Received Approval of SIMPONI.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 6
LIST OF TABLES
Number of Products Under Development for Chronic Plaque Psoriasis, 2010
Products under Development for Chronic Plaque Psoriasis – Comparative Analysis, 2010
Comparative Analysis by Late Stage Development, 2010
Comparative Analysis by Mid Clinical Stage Development, 2010
Comparative Analysis by Early Clinical Stage Development, 2010
Comparative Analysis by Pre-Clinical Stage Development, 2010
Johnson & Johnson, 2010
Boehringer Ingelheim GmbH, 2010
Abbott Laboratories, 2010
Amgen Inc., 2010
Eli Lilly and Company, 2010
GlaxoSmithKline plc, 2010
Biotest AG, 2010
Merck & Co., Inc., 2010
Nycomed International Management GmbH, 2010
Novartis AG, 2010
Astellas Pharma Inc., 2010
Galderma S.A., 2010
GTC Biotherapeutics, Inc., 2010
UCB Group, 2010
Incyte Corporation, 2010
Merck KGaA, 2010
Paladin Labs Inc., 2010
CombinatoRx, Incorporated, 2010
R-Tech Ueno, Ltd., 2010
Eisai Inc., 2010
REVOTAR Biopharmaceuticals AG, 2010
Therapeutics Incorporated, 2010
Vascular Biogenics Ltd., 2010
ISDIN, 2010
AB Science, 2010
Maruho Co.,Ltd., 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Discontinued Products 54
LIST OF FIGURES
Number of Products under Development for Chronic Plaque Psoriasis, 2010
Products under Development for Chronic Plaque Psoriasis – Comparative Analysis, 2010
Products under Development by Companies, 2010
Products under Investigation by Universities/Institutes, 2010
Late Stage Products, 2010
Mid Clinical Stage Products, 2010
Early Clinical Stage Products, 2010
Pre-Clinical Stage Products, 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products, 2010
Assessment by Route of Administration, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Assessment by Stage and Molecule Type, 2010 40
Global Markets Direct Report Coverage
Chronic Plaque Psoriasis Overview
Therapeutics Development
An Overview of Pipeline Products for Chronic Plaque Psoriasis
Chronic Plaque Psoriasis Therapeutics under Development by Companies
Chronic Plaque Psoriasis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Chronic Plaque Psoriasis Therapeutics Development
Johnson & Johnson
Boehringer Ingelheim GmbH
Abbott Laboratories
Amgen Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Biotest AG
Merck & Co., Inc.
Nycomed International Management GmbH
Novartis AG
Astellas Pharma Inc.
Galderma S.A.
GTC Biotherapeutics, Inc.
UCB Group
Incyte Corporation
Merck KGaA
Paladin Labs Inc.
CombinatoRx, Incorporated
R-Tech Ueno, Ltd.
Eisai Inc.
REVOTAR Biopharmaceuticals AG
Therapeutics Incorporated
Vascular Biogenics Ltd.
ISDIN
AB Science
Maruho Co.,Ltd.
Universities/Institutes Involved in Chronic Plaque Psoriasis Therapeutics Development
Chronic Plaque Psoriasis Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
ABT-874 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Calcipotriene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Halobetasol Propionate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Humira + Daivobet - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methotrexate + Enbrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NYC 0462 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Onercept_ - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Voclera - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Alga Dunaliella bardawil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Humira - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pioglitazone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Chronic Plaque Psoriasis - Featured News
Sep 14, 2010: Biotie's Phase I Trial With BTT-1023 Demonstrates Safety Profile
Oct 19, 2009: New Simponi Data Show Inhibition of Joint Damage in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
Oct 19, 2009: New Simponi Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
Oct 06, 2009: Simponi (golimumab) Receives European Approval As Once-Monthly Subcutaneous Anti-Tnf For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis With Novel Smartject Autoinjector.
Jun 25, 2009: SIMPONI(Golimumab) Receives Positive Opinion from Chmp for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Apr 24, 2009: Simponi (Golimumab) Receives FDA Approval As First Once-Monthly Anti-TNF For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis
Apr 13, 2009: Health Canada Approves Simponi™ (Golimumab) For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis
Sep 05, 2008: BioCryst Reports Results From BCX-4208 Phase IIa Trial In Subjects With Psoriasis
Apr 14, 2008: Medarex Received Approval of SIMPONI.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 6
LIST OF TABLES
Number of Products Under Development for Chronic Plaque Psoriasis, 2010
Products under Development for Chronic Plaque Psoriasis – Comparative Analysis, 2010
Comparative Analysis by Late Stage Development, 2010
Comparative Analysis by Mid Clinical Stage Development, 2010
Comparative Analysis by Early Clinical Stage Development, 2010
Comparative Analysis by Pre-Clinical Stage Development, 2010
Johnson & Johnson, 2010
Boehringer Ingelheim GmbH, 2010
Abbott Laboratories, 2010
Amgen Inc., 2010
Eli Lilly and Company, 2010
GlaxoSmithKline plc, 2010
Biotest AG, 2010
Merck & Co., Inc., 2010
Nycomed International Management GmbH, 2010
Novartis AG, 2010
Astellas Pharma Inc., 2010
Galderma S.A., 2010
GTC Biotherapeutics, Inc., 2010
UCB Group, 2010
Incyte Corporation, 2010
Merck KGaA, 2010
Paladin Labs Inc., 2010
CombinatoRx, Incorporated, 2010
R-Tech Ueno, Ltd., 2010
Eisai Inc., 2010
REVOTAR Biopharmaceuticals AG, 2010
Therapeutics Incorporated, 2010
Vascular Biogenics Ltd., 2010
ISDIN, 2010
AB Science, 2010
Maruho Co.,Ltd., 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Discontinued Products 54
LIST OF FIGURES
Number of Products under Development for Chronic Plaque Psoriasis, 2010
Products under Development for Chronic Plaque Psoriasis – Comparative Analysis, 2010
Products under Development by Companies, 2010
Products under Investigation by Universities/Institutes, 2010
Late Stage Products, 2010
Mid Clinical Stage Products, 2010
Early Clinical Stage Products, 2010
Pre-Clinical Stage Products, 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products, 2010
Assessment by Route of Administration, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Assessment by Stage and Molecule Type, 2010 40
